Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Stock Is Rebounding Today

By George Budwell - Oct 30, 2017 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

TransEnterix's shares are on the mend today, thanks to the buyout-rumor mill and an analyst upgrade.

What happened

TransEnterix (TRX -3.92%), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.

Prior to today's double-digit move, TransEnterix's stock had fallen by more than 40% following the FDA approval of its minimally invasive robotic-surgery system, Senhance, earlier this month, which initially sparked the company's shares to rise by more than 200% in a single day. 

Image of metallic balls knocking against each other.

Image source: Getty Images.

So what

The exact cause of this hefty rally, however, isn't altogether clear. TransEnterix's shares appear to be responding to both an unsubstantiated social media rumor of a potential buyout from Johnson & Johnson (JNJ 0.29%) that popped up over the weekend, as well as a new 12-month price target from analysts at Stifel Nicolaus. Specifically, Stifel's analysts hiked their price target from $3.75 to $4.00 this morning, citing a high interest from surgeons in Senhance. 

Now what

As I've argued before, TransEnterix would be wise to sell itself at this stage in the game. The company, after all, lacks the financial firepower to launch Senhance on its own, or to compete with the current market-share leader in robotic surgery in a meaningful way. 

That said, there's no concrete evidence that J&J -- or any other company for that matter -- is gearing up to make an offer. So, even though a buyout makes sense in a lot of ways, investors probably shouldn't put much stock in this baseless rumor.

All told, TransEnterix is an intriguing stock because of Senhance, but the company still has to figure out how to raise the capital required to back the system's commercial launch. And until that touchstone issue is resolved, I think investors may want to stick to the sidelines with this high-risk, high-reward robotic-surgery play.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tanzanian Gold Corporation Stock Quote
Tanzanian Gold Corporation
$0.37 (-3.92%) $0.02
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.51 (0.29%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.